

CV and Financial Disclosure of Board

Name: Jan C. van Meurs

Main Employment

Hospital and University Practice:

Location: the Rotterdam Eye Hospital and Erasmus Medical Center.

Position: vitreoretinal consultant, professor of Ophthalmology.

Curriculum Vitae

Medical School: Leiden University Medical School

Other Degrees: PhD "Ocular findings in sickle cell disease on Curacao".

Primary Fields of Interest: vitreoretinal surgery

Research Interests: surgery for AMD: RPE transplantation and hemorrhage displacement, retinal detachment, PVR, endophthalmitis

Other Interests:

Publications over past 5 years:

{{1-39}} please see below.

Financial Declaration for 2014

1) Payment to you directly for services you have provided (speaker fees, honoraria, consultancy, advisory board fees, investigator etc)

Company: (include all applicable companies)

Nothing to declare

Cell Cure Jerusalem, advisory board

Alcon, speaker fee on Jetrea symposium

2) Payment to your institution for services you have provided (speaker fees, honoraria, consultancy, advisory board fees, investigator etc)

Company: (include all applicable companies)

x Nothing to declare

3) Personal investment in a pharmaceutical or medical device company

Company: (include all applicable companies)

x Nothing to declare

4) Payment of royalties for intellectual property in a pharmaceutical or medical device company

Company: (include all applicable companies)

x Nothing to declare

5) Research funding received personally

Company: (include all applicable companies)

x Nothing to declare

6) Research funding received by your department or institution for research you are carrying out

Company: (include all applicable companies)

Nothing to declare

40.000 for PVR research, CORR

40.000 for AMD research, Stichting Coolsingel and MD Foundation

180.000 for 3 years for RD Research, ZonMW Foundation

7) Receive travel funding for meetings, full or partial

Company: (include all applicable companies)

Nothing to declare

8) Any other financial interests

Company: (include all applicable companies)

Nothing to declare

Possibly a partial patent in a vibration device to release tissue, DORC,, Zuidland, the Netherlands

1. Knulst AJ, Maaijwee K, Van Meurs JC, Wieringa PA, Breedveld P, Schutte S: **Micro-scale thermal tissue gripper**. *MinimInvasiveTherAllied Technol* 2009, **18**(1):8-14.
2. Maaijwee K, Van Den Biesen PR, Van Meurs JC: **Hyperfluorescence of the optic disc with indocyanine green angiography**. *Eye (Lond)* 2009, **23**(4):819-821.
3. Siewertsz van Resema W vdPPRPvMJC: **Hoofdstuk 14: Oogheekunde**. *Diagnose en Therapie* 2009.
4. Bali E, Feron EJ, Peperkamp E, Veckeneer M, Mulder PG, van Meurs JC: **Letter to the editor: author's reply. The effect of a preoperative subconjunctival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial**. *Graefes ArchClinExpOphthalmol* 2010, **249**:153-153.
5. Bali E, Feron EJ, Peperkamp E, Veckeneer M, Mulder PG, Van Meurs JC: **The effect of a preoperative subconjunctival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial**. *Graefes ArchClinExpOphthalmol* 2010, **248**:957-962.
6. Jousen A, van Meurs JC: **Sichelzellretinopathie**. In: *Atlas des Augeshintengrund*. edn. Edited by Heimann H KU. Stuttgart, New York: Thieme; 2010: 150-151.
8. Neubauer AS, Liakopoulos S, Van Meurs JC, Kirchhof B: **Cost-effectiveness of autologous retinal pigment epithelium and choroid translocation in neovascular AMD**. *IntJOphthalmol* 2010, **3**(3):228-233.
9. Braaf B, Vermeer KA, Sicam VA, van ZE, Van Meurs JC, de Boer JF: **Phase-stabilized optical frequency domain imaging at 1-microm for the measurement of blood flow in the human choroid**. *OptExpress* 2011, **19**(21):20886-20903.
10. Braaf B, Vermeer KA, Sicam VA, van Zeeburg E, van Meurs JC, de Boer JF: **Phase-stabilized optical frequency domain imaging at 1-microm for the measurement of blood flow in the human choroid**. *Opt Express* 2011, **19**(21):20886-20903.
11. Ganteris-Gerritsen E, Ugahary LC, Jansen J, Mulder PG, Cohen AF, Van Meurs JC: **Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma**. *Retina* 2011.
12. Reyniers R, Boekhoorn S, Veckeneer M, van MJ: **A case-control study of beneficial and adverse effects of 2-octyl cyanoacrylate tissue adhesive for episcleral explants in retinal detachment surgery**. *Graefes ArchClinExpOphthalmol* 2011.
13. Tukker AA, Knulst AJ, Maaijwee KJ, Schutte S, van Zeeburg EJ, Van Meurs JC, Dankelman J: **Single-sided and small-scaled grasping of delicate tissues: Effectiveness of indirect heat-induced attachment and detachment**. *MinimInvasiveTherAllied Technol* 2011.
14. van Bilsen K, van Hagen PM, Bastiaans J, Van Meurs JC, Missotten T, Kuijpers RW, Hooijkaas H, Dingjan GM, Baarsma GS, Dik WA: **The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha**. *BrJ Ophthalmol* 2011.
15. van BK, van Hagen PM, Bastiaans J, Van Meurs JC, Missotten T, Kuijpers RW, Hooijkaas H, Dingjan GM, Baarsma GS, Dik WA: **The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha**. *BrJOphthalmol* 2011, **95**(6):864-868.

16. van RJ, Boks AL, Sprenger A, Ossewaarde JM, Van Meurs JC: **The concentration of povidone-iodine for preoperative disinfection: relation to endophthalmitis incidence.** *AmJ Ophthalmol* 2011, **152**(2):321.
17. van Rooij J, Boks AL, Sprenger A, Ossewaarde JM, van Meurs JC: **The concentration of povidone-iodine for preoperative disinfection: relation to endophthalmitis incidence.** *Am J Ophthalmol* 2011, **152**(2):321; author reply 321-322.
18. van Zeeburg EJ, Cereda MG, van der Schoot J, Pertile G, van Meurs JC: **Early perfusion of a free RPE-choroid graft in patients with exudative macular degeneration can be imaged with spectral domain-OCT.** *Invest Ophthalmol Vis Sci* 2011, **52**(8):5881-5886.
19. van Zeeburg EJ, Cereda MG, van der SJ, Pertile G, Van Meurs JC: **Early perfusion of a free RPE-choroid graft in patients with exudative macular degeneration can be imaged with spectral domain-OCT.** *Invest Ophthalmol Vis Sci* 2011, **52**(8):5881-5886.
20. Ganteris-Gerritsen E, Ugahary LC, Jansen J, Mulder PG, Cohen AF, Van Meurs JC: **Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma.** *Retina* 2012, **32**(4):742-747.
21. Hoevenaars NE, Gans D, Missotten T, van RJ, Lesaffre E, Van Meurs JC: **Suspected Bacterial Endophthalmitis following Intravitreal Anti-VEGF Injection: Case Series and Literature Review.** *Ophthalmologica* 2012.
22. Hoevenaars NE, Gans D, Missotten T, van Rooij J, Lesaffre E, van Meurs JC: **Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: case series and literature review.** *Ophthalmologica* 2012, **228**(3):143-147.
23. Pastor-Idoate S, Rodriguez-Hernandez I, Rojas J, Fernandez I, Garcia-Gutierrez MT, Ruiz-Moreno JM, Rocha-Sousa A, Ramkissoon Y, Harsum S, MacLaren RE *et al*: **The p53 Codon 72 Polymorphism (rs1042522) is Associated with Proliferative Vitreoretinopathy: The Retina 4 Project.** *Ophthalmology* 2012.
24. Reyniers R, Boekhoorn S, Veckeneer M, van MJ: **A case-control study of beneficial and adverse effects of 2-octyl cyanoacrylate tissue adhesive for episcleral explants in retinal detachment surgery.** *Graefes Arch Clin Exp Ophthalmol* 2012, **250**(2):311-312.
25. Tukker AA, Knulst AJ, Maaijwee KJ, Schutte S, Van Zeeburg EJ, Van Meurs JC, Dankelman J: **Single-sided and small-scaled grasping of delicate tissues: effectiveness of indirect heat-induced attachment and detachment.** *Minim Invasive Ther Allied Technol* 2012, **21**(6):388-395.
26. van Meurs JC, Joussen A, Luttj G: **Zichelzellretinopathie.** In: *Retinale Gefaesserkrankungen.* edn. Berlin-Heidelberg: Springer; 2012: 406-425.
27. van Zeeburg EJ, Maaijwee KJ, Missotten TO, Heimann H, van Meurs JC: **A free retinal pigment epithelium-choroid graft in patients with exudative age-related macular degeneration: results up to 7 years.** *Am J Ophthalmol* 2012, **153**(1):120-127.e122.
28. Bastiaans J, van Meurs JC, van Holten-Neelen C, Nagtzaam NM, van Hagen PM, Chambers RC, Hooijkaas H, Dik WA: **Thrombin induces epithelial-mesenchymal transition and collagen production by retinal pigment epithelial cells via autocrine PDGF-receptor signaling.** *Invest Ophthalmol Vis Sci* 2013, **54**(13):8306-8314.
29. Bastiaans J, Van Meurs JC, van Holten-Neelen C, Nijenhuis MS, Kolijn-Couwenberg MJ, van Hagen PM, Kuijpers RW, Hooijkaas H, Dik WA: **Factor Xa and thrombin stimulate proinflammatory and profibrotic mediator production by retinal pigment epithelial cells: a role in vitreoretinal disorders?** *Graefes Arch Clin Exp Ophthalmol* 2013.
30. Pastor-Idoate S, Rodriguez-Hernandez I, Rojas J, Fernandez I, Garcia-Gutierrez MT, Ruiz-Moreno JM, Rocha-Sousa A, Ramkissoon Y, Harsum S, Maclaren RE *et al*: **The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: the Retina 4 Project.** *Ophthalmology* 2013, **120**(3):623-628.

31. Rojas J, Fernandez I, Pastor JC, MacLaren RE, Ramkissoon Y, Harsum S, Charteris DG, Van Meurs JC, Amarakoon S, Ruiz-Moreno JM *et al*: **A Genetic Case-Control Study Confirms the Implication of SMAD7 and TNF Locus in the Development of Proliferative Vitreoretinopathy**. *Invest OphthalmolVisSci* 2013, **54**(3):1665-1678.
32. van Zeeburg EJ, Cereda MG, Van Meurs JC: **Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm**. *Graefes ArchClinExpOphthalmol* 2013, **251**(3):733-740.
33. van Zeeburg EJ, Van Meurs JC: **Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration**. *Ophthalmologica* 2013, **229**(1):1-14.
34. Bastiaans J, van Meurs JC, Mulder VC, Nagtzaam NM, Smits-te Nijenhuis M, Dufour-van den Goorbergh DC, van Hagen PM, Hooijkaas H, Dik WA: **The role of thrombin in proliferative vitreoretinopathy**. *Invest Ophthalmol Vis Sci* 2014, **55**(7):4659-4666.
35. Bharti K, Rao M, Hull SC, Stroncek D, Brooks BP, Feigal E, van Meurs JC, Huang CA, Miller SS: **Developing cellular therapies for retinal degenerative diseases**. *Invest Ophthalmol Vis Sci* 2014, **55**(2):1191-1202.
36. Lindstedt EW, Bennebroek CA, van der Werf DJ, Veckeneer M, Norel AO, Nielsen CC, Wubbels RJ, van Dissel JT, van Meurs JC: **A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results**. *Graefes Arch Clin Exp Ophthalmol* 2014.
37. Rojas J, Fernandez I, Pastor JC, MacLaren RE, Ramkissoon Y, Harsum S, Charteris DG, Van Meurs JC, Amarakoon S, Garcia-Arumi J *et al*: **Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables**. *Br J Ophthalmol* 2014.
38. van Zeeburg EJ, Maaijwee K, van Meurs JC: **There is no relation between the occurrence of proliferative vitreoretinopathy and the location of the donor site after transplantation of a free autologous retinal pigment epithelium-choroid graft**. *Acta Ophthalmol* 2014, **92**(3):228-231.
39. Veckeneer M, Maaijwee K, Charteris DG, van Meurs JC: **Deferred laser photocoagulation of relaxing retinotomies under silicone oil tamponade to reduce recurrent macular detachment in severe proliferative vitreoretinopathy**. *Graefes Arch Clin Exp Ophthalmol* 2014.